GLENMARK5 months ago
Glenmark Pharmaceuticals Limited Announces New Development Candidate ISB 2301
Glenmark Pharmaceuticals Limited announces new development candidate ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumors.